Business
Seamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss
-- Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient recombinases with Lilly’s extensive development expertise in genetic hearing disorders -- -- Companies will leverage Seamless’ recombinase technology to develop therapeutics for defined hearing loss indications -- Dresden, Germany, and Lexington, MA, January 28, 2026 – Seamless Therapeutics announced today that it has entered into a strategic global re
About this update from Eli Lilly And Company
[{"type":"image","alt":"Seamless Therapeutics","displaySize":"","headline":null,"caption":"Seamless Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":105,"url":"https://media.zenfs.com/en/globenewswire.com/d6605e9fe5f51bdbdf03502a806e8345"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LZboY.BL4gUFRe9P3ZofVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d6605e9fe5f51bdbdf03502a806e8345","width":300,"height":105}},"lazy":false},{"type":"text","content":"-- Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient recombinases with Lilly’s extensive development expertise in genetic hearing disorders --","length":235,"tagName":"p"},{"type":"text","content":"-- Companies will leverage Seamless’ recombinase technology to develop therapeutics for defined hearing loss indications --","length":123,"tagName":"p"},{"type":"text","content":"Dresden, Germany, and Lexington, MA, January 28, 2026 – Seamless Therapeutics announced today that it has entered into a strategic global research collaboration and licensing agreement with Eli Lilly and Company (“Lilly”) to develop and commercialize programmable recombinase-based treatments targeting hearing loss indications, using Seamless’ proprietary recombinase platform. The company’s technology performs large, precise DNA insertions in any target gene sequence, and operates independent of the cell’s natural DNA repair pathway.","length":538,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Seamless will design and program site-specific recombinases directed to correct mutations in certain genes of interest related to hearing loss. Lilly will receive an exclusive license to the programmed recombinases to advance through preclinical and clinical drug development and commercialization.","length":332,"tagName":"p"},{"type":"text","content":"“Lilly is invested in advancing novel treatment approaches for genetic diseases and shares our vision of bringing genetic medicines to patients who currently have limited treatment options. This collaboration is a validation of our gene editing platform and its broad disease-modifying potential,” said Albert Seymour, Ph.D., Chief Executive Officer of Seamless Therapeutics. We look ...